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Abstract
Hepatocellular carcinoma (HCC) is one of the most lethal and prevalent cancers in humans. The
molecular mechanisms leading to the development of HCC are extremely complicated and consist
of prominent genetic, genomic, and epigenetic alterations. This review summarizes the current
knowledge of the role of epigenetic aberrations, including changes in DNA methylation, histone
modifications, and expression of microRNAs in the pathogenesis of HCC. It also emphasizes that
identification of the underlying epigenetic alterations that drive cell transformation and promote
development and progression of HCC is crucially important for understanding mechanisms of
hepatocarcinogenesis, its detection, therapeutic intervention, and prevention.
1. Introduction
Hepatocellular carcinoma (HCC) is one of the most prevalent life-threatening human
cancers that is not only increasing in worldwide incidence in the past decade [1–4], but is
also a leading cause of cancer-related deaths worldwide [3–6]. HCC is an aggressive and
enigmatic disease, which represents approximately 85% of liver cancers [5,6]. The most
prominent etiological factors associated with HCC consist of chronic viral hepatitis B and C
infections [4,7–9], nonalcoholic fatty liver disease [10–12], and toxin and alcohol exposure
[6,9]. The development and progression of HCC is a multistep and long-term process
characterized by the progressive sequential evolution of morphologically distinct
preneoplastic lesions (formed as a result of chronic liver injury, necro-inflamation and
regeneration, small cell dysplasia, low-grade and high-grade dysplastic nodules) that
culminates in the formation of HCC [5,13]. However, the molecular and cellular
mechanisms of HCC pathogenesis are still poorly understood [5,6].
Traditionally, the development of HCC in humans has been viewed as a progressive
multistep process of transforming of normal cells into malignant driven primarily by the
stepwise accumulation of genetic alterations in tumor-suppressor genes and oncogenes [14–
16], with mutations in β-catenin and P53 genes being the major genetic alterations [14,15].
However, over the past decade there has been a surge in data indicating the importance of
epigenetic processes, which has largely changed the view of HCC as a genetic disease only
[17–19]. Presently, HCC is recognized as both a genetic and epigenetic disease, and genetic
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and epigenetic components cooperate at all stages of liver carcinogenesis [16,20]. While the
sequential accumulation of various genetic changes in hepatocarcinogenesis has been
extensively studied, the contribution of epigenetic alterations to HCC development and
progression has remained relatively unexplored until recently [17–19].
2. Epigenetic alterations in HCC
The unifying molecular feature of HCC is a profoundly reshaped epigenome that is
characterized by global genomic hypomethylation, gene-specific DNA hyper- or hypo-
methylation, abnormal expression of DNA methyltransferases and histone modifying
enzymes, altered histone modification patterns, and aberrant expression of microRNAs
[6,13].
2.1. Global DNA hypomethylation in human HCC
DNA hypomethylation signifies one of the two major DNA methylation states and refers to
a condition in which there is a decrease in the number of methylated cytosine bases from the
“normal” methylation level. DNA hypomethylation arises mainly from the loss of
methylation at normally heavily methylated areas of genome. The molecular events that may
lead to hypomethylation of DNA are elusive and it is likely that multiple pathways may be
involved. Hypomethylation of DNA can be achieved either passively or actively. Passive
loss of methylated cytosines in the genome may be a consequence of either (i) limited
availability of the universal methyl donor S-adenosyl-L-methionine (SAM), (ii)
compromised integrity of DNA, or (iii) altered expression and/or activity of DNA
methyltransferases (DNMTs) [21].
The methyl groups needed for DNA methylation and other cellular methylation reactions are
acquired from SAM, which is synthesized from L-methionine and adenosine in an ATP-
dependent reaction catalyzed by methionine adenosyltransferase 1 (MAT1) in a one-carbon
pathway in the cytosol of every cell. The liver is the primary tissue for SAM biosynthesis
and degradation [22]. This indispensably connects faithful DNA methylation to the proper
functioning of this metabolic pathway. It is well established that either genetic
polymorphism in genes involved in the methyl-group metabolism, or deficiencies in methyl
group donors caused by endogenous and exogenous factors, may lead to loss of cytosine
methylation in DNA [23,24].
The integrity of the genome is another critical factor that may affect the DNA methylation
status. Specifically, the results of several studies have demonstrated that the presence of
unrepaired lesions in DNA, e.g., 8-oxodeoxyguanosine, 5-hydroxymethyl-cytosine, apurinic/
apirimidinic sites, and strand breaks, diminishes the ability of DNA methyl transferases
(DNMTs) to methylate DNA [25,26]. Additionally, a large body of evidence clearly
demonstrates that improper function of DNMTs may compromise the DNA methylation
status [27]. Importantly, a number of well-established hepatocarcinogens may perturb the
described above processes and trigger loss of DNA methylation in the liver [19,28,29].
Active loss of methylated cytosines, via an active replication-independent DNA
demethylation process, was controversial and inconclusive for many years [30,31].
However, recent studies have provided compelling experimental evidence that active loss of
DNA methylation is associated with the function of DNA repair machinery [32–35].
The loss of DNA methylation was the first epigenetic abnormality and one of the most
common molecular alterations identified in human cancers [36], including HCC [37,38].
Global DNA demethylation in HCC primarily affects stable, methylated areas of the genome
composed predominantly of repetitive DNA sequences, such as long interspersed nucleotide
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elements 1 (LINE1), retroviral intracesternal A particles (IAP), Alu elements, and body of
genes [39]. Indeed, the results of several comprehensive studies have demonstrated
extensive hypomethylation of LINE-1, ALU, and SAT2 repetitive elements in HCC [40–
42]. More importantly, it has been demonstrated that the serum LINE-1 hypomethylation
may be an independent prognostic marker in patients with HCC [43].
There are several molecular consequences of global DNA demethylation that may contribute
to the progression of liver carcinogenesis via multiple mechanisms. Specifically, genomic
hypomethylation may cause a significant elevation in mutation rates, aberrant activation of
“normally” silenced tumor-promoting genes, loss of imprinting, and activation and
transposition of repetitive DNA elements leading to chromosomal and genomic instability
[44].
Despite the large body of evidence indicating that cancer-associated DNA demethylation is
an important early event in the development of HCC, it is still less clear if the loss of DNA
methylation is a cause or a consequence of the malignant transformation [45]. The notion
that DNA hypomethylation plays a causative role in liver cancer is based on the results of
nutritional and genetic studies using “lipogenic methyl-deficient diets” [46–48] or
genetically-engineered ApcMin/+;Dnmt1chip/c mice [49], respectively. In contrast, there is
also evidence that cancer-linked DNA hypomethylation may be a passive inconsequential
side effect of carcinogenesis [45]. The latter is evidenced by the facts that not all liver
tumors exhibit DNA hypomethylation [50] and not all carcinogenic processes are
accompanied by the loss of DNA methylation [51].
2.2. Cancer-linked gene-specific DNA hypermethylation in human HCC
DNA hypermethylation is the state where the methylation of “normally” undermethylated
DNA domains, those that predominantly consist of CpG islands [52], increases. CpG islands
are defined as the genomic regions that contain the highest G + C content, have a high
frequency of CpG dinucleotides, are at least 400–500 bp long, and are located in intragenic,
intergenic, or 5′ ends of genes [53–55]. However, only CpG islands that span the 5′ regions
of promoters and first exons are mainly unmethylated. For instance, it is established that less
than 3% of CpG islands in gene promoters are methylated [55].
The focus of studies aimed to explore the role of DNA methylation in HCC has been on
global epigenomic alterations in HCC, abnormal gains of DNA methylation
(hypermethylation) of typically unmethylated CpG island-containing promoters,
transcriptional repression, and loss of gene function. Specifically, gene-specific DNA
hypermethylation has gathered most attention as a critical event in liver carcinogenesis.
Several epigenetically inactivated genes, as evidenced by association between diminished
mRNA levels with highly methylated promoters, have been identified in HCC. Among
genes frequently methylated in HCC are tumor suppressors, including RASSF1A [56],
p16INK4A [57,58], p15INK4B [59], RB1 [60], SOCS1 [61,62], SOCS3 [63], SYC [64], GSTP1
[65], NQO1 [66], PROX1 [67,68], NORE1B [69], RIZ1 [70], RELN [71], FBLN1 [72], and
PAX5 [73]. These genes are involved in the regulation of vital biological processes,
including cell-cycle control, apoptosis, cell proliferation, and xenobiotic metabolism.
In addition, there is growing evidence of the importance of non-CpG island-containing
promoter coding region hypermethylation in gene inactivation. For instance,
hypermethylation of the p53 promoter region and the MAT1A coding region is associated
with inhibition of gene expression in human HCC [74,75]. The fact that the aberrant gene-
specific hypermethylation of the aforementioned genes occurs not only in HCC, but also in
premalignant pathological conditions, including chronic viral hepatitis B and C and liver
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cirrhosis, suggests the importance of gene-specific hypermethylation event in pathogenesis
and progression of HCC.
2.3. Cancer-linked gene-specific DNA hypomethylation in human HCC
Until recently, the majority of the studies in the field of cancer research, including liver
cancer, have focused on alterations in DNA hypomethylation, mainly hypomethylation of
repetitive sequences, and epigenetically-driven gene silencing, as the main mechanisms
favoring the development of HCC. However, mounting evidence indicates that the
hypomethylation of “normally” methylated genes is significant in the pathogenesis of HCC
[76]. Currently, a number of hypomethylated tumor-promoting genes, including uPA [77],
HPA [78], SNCG [79], TFF3 [80], MAT2A [81], HKII [82], CD147 [83], and VIM [84] have
been identified in primary human HCC.
Importantly, gene-specific DNA methylation changes, both hyper- and hypomethylation, in
HCC are associated with well-established hallmarks of cancer, including the acquisition of
persistent proliferative signaling, resistance to cell death, evasion of growth suppression,
replicative immortality, inflammatory response, deregulation of energy metabolism,
induction of angiogenesis, and activation of invasion [85]. However, while gene-specific
promoter DNA hypermethylation changes are associated predominantly with deregulation of
pathways important for the initiation of HCC, such as cell-cycle control, apoptosis, and cell
proliferation, gene-specific promoter DNA hypomethylation changes are related to
biological processes critical for tumor progression, including cell growth, cell
communication, adhesion and mobility, signal transduction, and drug resistance.
The existence of two opposing hyper- and hypomethylation events in the same functional
pathways complement or enhance each other in the disruption of cellular homeostasis
favoring progression of HCC. For instance, hypermethylation and transcriptional
inactivation of the E-cadherin (CDH1) gene [86] and hypomethylation-induced up-
regulation of the Vimentin (VIM) gene [84] in HCC may exaggerate invasion and escalate
further progression of HCC.
2.4. Alterations of DNA methyltransferases in human HCC
Abnormal patterns of DNA methylation in HCC is closely related to the disruption in the
functioning of DNA methylation machinery. Several reports distinctly established the major
role of altered gene expression of DNA methyltransferase DNMT1, a main enzyme involved
in the maintenance of genomic methylation patterns, the de novo DNA methyltransferases
DNMT3A and DNMT3B, and methyl-binding proteins in the development and progression
of HCC [27,87–89]. This is evidenced by a progressive marked up-regulation of DNMT1,
DNMT3A, and DNMT3B in premalignant non-cancerous liver tissues and in full-fledged
HCC [27] and by the fact that over-expression of these DNMTs significantly correlated with
CpG-island hypermethylation of tumor-related genes [90]. Additionally, it has been
demonstrated that over-expression of DNMT3B4, a splice variant of DNMT3B, causes
DNA hypomethylation in pericentromeric satellite regions [44].
2.5. Dysregulation of histone modifications in human HCC
DNA methylation changes in HCC are not isolated events; they occur in an environment of
large-scale disruptions of the cellular epigenome that also include alterations in histone
modification patterns [91]. Similarly to alterations in DNA methylation, changes in histone
modifications in HCC occur genome-wide and on gene-specific scales. At least eight
different classes of post-translational modifications, including methylation, acetylation,
phosphorylation, ubiquitynation, sumoylation, biotinylation, and ADP-ribosylation have
been identified on the core histones H2A, H2B, H3, H4, and the H1 family of linker histones
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[92]. With respect to HCC, acetylation and methylation of histone lysine residues are the
best studied histone modifications so far. Typically, histone acetylation is associated with an
active transcription, whereas methylation may be associated with either active or repressive
states, depending on the modified site [91,92].
Currently, it is well-documented that transcriptional silencing of cancer-related genes in
HCC is associated with DNA methylation and/or histone modifications at their promoters.
For instance, a number of transcriptionally repressed genes in human HCC are associated
either with hypoacetylation of lysine residues at histone H3 and H4 [66,93]. Likewise,
transcriptionally silenced RIZ1, p16INK4A and RASSF1A tumor-suppressor genes in human
HCC are characterized by an increased level of repressive histone H3 lysine 9 and histone
H3 lysine 27 methylation marks at their promoters [70,94,95] In addition to aberrations in
histone modifications at promoters of individual genes, HCC also displays genome-wide
changes in histone modifications, particularly a loss of trimethylation of histone H4 lysine
20 and increase of histone H3 lysine 27 trimethylation and histone H3 phosphorylation
[96,97].
2.6. Alterations of histone modifying enzymes in human HCC
It is well-documented that HCC is characterized by a prominent dysregulation of several
histone-modifying enzymes, including histone deacetylase (HDAC) class I isoforms
HDAC1, HDAC2, and HDAC3, SIRT1, a class III HDAC, and histone methyltransferases
(HMTs) SMYD3, RIZ1, and EZH2 [98–102]. Histone deacetylases are responsible for
removal of an acetyl group from lysine residues of target proteins and display multi-faceted
roles in coordinating the interaction of intracellular signaling pathways through chromatin
remodeling. Several recent studies have demonstrated an elevated expression of HDAC1,
HDAC2, and HDAC3 [97,99] and SIRT1 in human HCC [103,104] that correlated with
clinicopathological features and recurrence of HCC.
Histone methyltransferases SMYD3, RIZ1, and EZH2 are responsible for methylation of
lysine residues 4, 9 and 27 at histone H3, respectively [99,100]. The up-regulation of the
SMYD3 HMT promotes proliferation of HCC via increasing H3 lysine 4 methylation, a
mark of transcriptional activation, and thus subsequent activation of downstream genes,
including NKX2-8 gene [99], which is frequently up-regulated in human HCC [105]. In
contrast, over-expression of the EZH2 in HCC may facilitate the progression of HCC
through increasing trimethylation of H3 lysine 27 and enhancing heterochromatin formation
at promoters of transcriptionally silenced genes [100]. Indeed, a recent report by Cheng et
al. [106] has demonstrated that EZH2 inserts its oncogenic activity in HCC through EZH2-
mediated epigenetic silencing of the growth-suppressive Wnt antagonists, which causes a
constitutive activation of Wnt/β-catenin signaling and proliferation of HCC cells.
Additionally, EZH2 recruits DNA methyltransferases to the EZH2-containing Polycomb
complex leading to de novo methylation of cancer-related genes [107,108].
In contrast, down-regulation of RIZ1 HMT that is frequently found in HCC [70,109] may
promote progression of hepatocarcinogenesis via reduction of the level of histone H3 lysine
9 trimethylation, followed by chromatin decondensation, and genomic instability.
Additionally, prominent epigenetic abnormalities found in HCC may be induced by
alterations in intracellular metabolism. For example, the status of DNA and histone
methylation in HCC may be compromised by deficiency of intracellular SAM caused by
cancer-related transcriptional silencing of the liver-specific MAT1A gene [110,111]. This
gene encodes methionine adenosyltransferase, which is an essential enzyme for the
biosynthesis SAM [112]. Likewise, expression of several other genes involved in
methionine metabolism, e.g., BHMT and CBS, is reduced in HCC [110. This corresponds to
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a recently emerged hypothesis that alteration of cellular epigenome in cancer is associated
with cancer-linked metabolic disturbances, specifically with aberrant levels of variety of
small molecules derived from intermediary intracellular metabolism, including glucose,
glutathione, flavin adenine dinucleotide and nicotine adenine dinucleotide, folate, acetyl
coenzyme A, and α-ketoglutarate [113,114].
2.7. MicroRNAome alterations in human HCC
Extensive studies in the past decade have indicated the existence and importance of another
epigenetic mechanism of regulation of gene function by means of small non-coding
microRNAs (miRNAs). Currently, miRNAs are recognized as one of the major regulatory
gatekeepers of protein-coding genes in the human genome [115]. MiRNAs are small 16–29
nucleotide-long non-coding RNAs that primarily function as negative gene regulators at the
post-transcriptional level [116]. MiRNAs are generated by RNA polymerase II or RNA
polymerase III as long primary transcripts, primary miRNAs. Following transcription,
primary miRNAs form a stem-loop structure, which is recognized and processed by the
RNase III-type enzyme Drosha creating precursor miRNAs. These precursor miRNAs are
transported from the nucleus to the cytoplasm by Exportin-5. In the cytoplasm, the pre-
miRNAs are further processed by Dicer, an RNase III enzyme, generating miRNA:miRNA
hybrids. After unwinding, one strand of the duplex is degraded, and another strand becomes
a mature miRNA. MiRNAs can induce mRNA cleavage if their complementary to the 3′-
untranslated region of mRNA targets are perfect or miRNAs can induce translational
repression if complementarity is imperfect [115].
Currently there are more than 700 mammalian miRNAs that can potentially target up to one-
third of protein-coding genes involved in development, cell differentiation, metabolic
regulation, signal-transduction, cell proliferation, and apoptosis. As the deregulation of these
very same biological processes is a hallmark of cancer [85], it has been suggested that
changes in miRNA expression might have significance in cancer [117–119], including HCC
[120,121]. In recent years, a number of comprehensive studies have documented an aberrant
expression, both up-regulation and down-regulation, of miRNAs that have been associated
with virtually every aspect of HCC biology, including tumor progression, e.g., up-regulated
miR-21, miR-17-92, miR-155, miR-191, and miR-221/miR-222 and down-regulated
miR-122 [122–126], invasion and metastasis, e.g., up-regulated miR-21 and miR-151 and
down-regulated miR-200 family [122,127,128], and acquisition of resistance of malignant
cells to various chemotherapeutic agents, e.g., up-regulated miR-21 and down-regulated
miR-122 and miR-199a-3p [129–131].
Growing evidence indicates a direct and interdependent link between epigenetic and miRNA
expression alterations illustrating the complexity of epigenetic abnormalities in HCC. For
instance, high expression of miR-191 in HCC is associated with hypomethylation of the
mir-191 gene [132], whereas down-regulation of miR-1, miR-124, miR-125b, and miR-203
is attributed to DNA hypermethylation [133–135]. On the other hand, altered expression of
miR-29, miR-152, and miR-200a causes substantial alterations in DNA methylation and
histone modifications [136–138].
3. Molecular diagnosis of HCC: epigenetic biomarkers
Understanding the molecular mechanisms involved in neoplastic hepatocyte transformation,
promotion, and progression of hepatocarcinogenesis are crucial for the diagnosis, prognosis,
and determination of treatment strategies of HCC. The post-genomic era molecular tools,
e.g., transcriptomic and genome-wide association studies, have been used succesfully for the
identification of new diagnostic and prognostic biomarkers of HCC [139–142]. Mapping the
patterns of DNA methylation has also been proposed recently as a valuble molecular
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diagnostic tool for HCC. Here we show the proposed chronology of epigenetic events in the
progression of human HCC (Figure 1).
Many studies provide evidence that cancer-linked DNA methylation alterations may be used
as early indicators of liver carcinogenesis, as well as prognostic markers of cancer
progression and response to chemotherapy [143–149]. Specifically, using a DNA
methylation profiling approach it is possible to differentially diagnose HCC from
preneoplastic lesions, e.g. low-grade and high-grade dysplastic nodules and cirrhosis
[143,146]. This is evidenced by different pattern and magnitude of gene-specific DNA
methylation changes in preneoplastic livers and full-fledged HCC. Recently, Nagashio et al.
[144] was able to predict HCC with 95.6% sensitivity and 100% specificity using a
quantification of DNA methylation level approach in preneoplastic liver tissue. These
authors also demonstrated that the methylation status of gene-specific DNA regions
significantly correlates with the outcome of patients with HCC. More importantly, the
results of several comprehensive studies have demonstrated clearly that aberrant gene-
specific DNA methylation patterns discriminate HCC, with an etiology associated with viral
hepatitis B and C infection and alcohol intake [146–151]. Additionally, several reports have
indicated that gene-specific methylation, e.g, RIZ1 gene, in surgically resected non-
tumorous tissue significantly associated with reoccurrence of HCC [152,153].
The steadiness and specificity of cancer-associated DNA hypo- or hypermethylation
changes offer substantial advantages over other molecular markers for cancer diagnostics.
Firstly, DNA hypermethylation is a positive signal not observed in normal cells, and
therefore it is independent of contamination with normal cells. Secondly, because DNA
methylation changes are stable, the same aberrant DNA methylation patterns specific for the
primary tumor can be identified in plasma and other body fluids. Indeed, several studies
have shown that promoter hypermethylation of cancer-related genes, including p16INK4A,
RASSF1A, GSTP, and RUNX3 genes [154–159], as well as LINE-1 hypomethylation [43]
were detected in the plasma of the majority of patients diagnosed with HCC. Such
observations indicate that cancer-linked aberrant DNA methylation may be a potential
valuable noninvasive diagnostic and prognostic biomarker for HCC.
Little evidence has been presented to clarify whether or not miRNA alterations may
distinguish HCC from preneoplastic lesions; however, similar to DNA methylation changes,
emerging evidence indicates that hepatic miRNA profile may predict the recurrence of HCC
after resection [160] and circulatory blood miRNA levels may be used as a potential
biomarker for noninvasive diagnosis of HCC [161–163].
4. Animal models of HCC
In humans, most of the research on HCC is conducted on patients who have already
developed the disease. This limits the scope of the investigation to tumor biology and does
not allow extensive study into the mechanisms of disease progression, which is critical for
early diagnostic and successful treatment. On the contrary, relevant animal models of liver
carcinogenesis provide a unique opportunity to understand the underlying molecular
mechanisms involved in pathogenesis of HCC and substantially complement many
shortcomings of humans-only studies [164–166]. The application of animal models to study
process of hepatocarcinogenesis is further supported by a recent evidence [167] showing
that despite major differences in etiology of mouse and human HCC (human HCC arises
predominantly within an environment of chronic inflammation, hepatocellular degeneration,
necrosis and regeneration, fibrosis and cirrhosis [168]) there are great similarities in the
molecular landscape between human and spontaneous HCC in B6C3F1 mice.
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The most commonly used animal models of HCC consist of those that are induced by
different genotoxic chemical carcinogens, e.g., diethylnitrosamine, aflatoxin B1, and 2-
acetylaminofluorene, non-genotoxic chemical agents, e.g., peroxisome proliferators,
transgenic mouse models of hepatitis B and C viral infection, and constitutive and
conditional transgenic mice with over-expression of oncogenes, e.g., c-myc and β-catenin, or
growth factors, e.g., TGFα, TGFβ, EGF, and PDGF-C [164–166]. One of the most
extensively studied models of rodent HCC that is relevant to humans is endogenous liver
carcinogenesis induced by dietary methyl deficiency [169]. This model is unique because
dietary omission of sources of methyl groups, rather than xenobiotic addition, leads to tumor
formation. In addition, the sequence of pathological and molecular events is remarkably
similar to the development of human HCC that is associated with viral hepatitis B and C
infections, alcohol exposure, and metabolic liver diseases, all of which are currently
considered major risk factors of HCC worldwide.
5. Perspectives
It is clear that epigenetic alterations are critical determinants of human hepatocellular
cancer. The progressive accumulation of epigenetic changes during development of HCC
gives a unique opportunity to use them as biomarkers in cancer detection. However, not all
aberrations may be equally important for the tumorigenic process [170]. Specifically, it is
highly unlikely that all epigenetic aberrations play a significant role in hepatocarcinogenesis.
For example, some epigenetic changes may drive other events that contribute to the
formation of a transformed phenotype, while others may be passenger events that
accompany the transformation process. In this respect, the identification of alterations that
drive cell transformation and promote hepatocarcinogenesis is crucially important for
understanding mechanisms of HCC progression and prevention. Additionally, the presence
of epigenetic abnormalities in premalignant and non-tumorous livers unequivocally indicates
the involvement of an “epigenetic field cancerization” effect in the pathogenesis of HCC
[90,143,152,153,171–174]. This emphasizes the role and the usefulness of epigenetic
biomarkers for early detection and prediction of HCC development. More importantly, the
potential reversibility of epigenetic alterations opens a novel mechanism-based approach to
molecular-targeted HCC treatment and prevention.
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